Skip to main content
NewslettersWatchlist

Outlook Therapeutics Inc(OTLK-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low7.18
Day High7.92
Open:7.34
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Outlook Therapeutics, Inc. - OTLK
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Outlook Therapeutics, Inc. - OTLK
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Outlook Therapeutics, Inc. - OTLK
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Outlook Therapeutics, Inc. - OTLK
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Outlook Therapeutics, Inc. - OTLK
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Outlook Therapeutics, Inc. - OTLK
PR Newswire
Outlook Therapeutics, Inc. (OTLK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm
Motley Fool
Why Shares of Outlook Therapeutics Rose Tuesday
ACCESSWIRE
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
Baystreet
Farewell, 2022
Globe Newswire
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones
Globe Newswire
Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference
Globe Newswire
Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note
Globe Newswire
Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010
Globe Newswire
Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD
Globe Newswire
Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Globe Newswire
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update
Globe Newswire
Outlook Therapeutics to Participate in Retina World Congress 2022
Globe Newswire
Outlook Therapeutics to Participate at the Virtual Investor 2022 CEO Spotlight
Globe Newswire
BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics
Globe Newswire
Outlook Therapeutics to Present at Wet AMD and DME Drug Development Summit
Globe Newswire
Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD
Globe Newswire
Outlook Therapeutics Bolsters Commercialization Expertise with Appointment of Alicia Tozier as Senior Vice President of Marketing and Market Access
Globe Newswire
Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific Congress
Globe Newswire
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update
Globe Newswire
Outlook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Globe Newswire
Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations
Globe Newswire
Outlook Therapeutics to Present at the Fourth Annual Telluride Retina Film Festival
Globe Newswire
Outlook Therapeutics Provides a Corporate Update and Business Outlook
Globe Newswire
Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference
AccessWire
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
Globe Newswire
Outlook Therapeutics to Present at the H.C. Wainwright BioConnect Conference

Profile

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as Oncobiologics Inc., is based in Cranbury, United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.